ArticleThe oncologist2020
Predicting Chemotherapy Toxicity in Older Patients with Cancer: A Multicenter Prospective Study.
Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07163169 (Correlation and Comparison Analyses of CARG, G8, and Frailty Tests in Predicting Chemotherapy-Associated Toxicity), which is not on this map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation and Comparison Analyses of CARG, G8, and Frailty Tests in Predicting Chemotherapy-Associated Toxicity: A Prospective Study
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predictive value of the Cancer and Aging Research Group Score for chemotherapy toxicities in older adults with cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Pooled it
- Frailty and outcomes in adults undergoing systemic anticancer treatment: a systematic review and meta-analysis.Journal of the National Cancer Institute · 2025Pooled it
- Modeling Cancer Outcomes and Economic Impact of the Anti-PD-1/PD-L1 Immunotherapy in the Gulf: United Arab Emirates, Oman, and Kuwait.Clinical drug investigation · 2026Article
- Article
- Review
- Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70-79 vs ≥ 80 years: a large-scale registry analysis.Archives of gynecology and obstetrics · 2026Article
- Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.Cancer · 2026Article
- Article
- Distinct Symptom Profiles in Younger and Older Patients With Cancer Receiving Chemotherapy.Cancer medicine · 2026Article
- Network analysis of distress, symptom burden, social support, and digital health literacy in older postoperative patients with gastric cancer.Frontiers in psychiatry · 2026Article
- Incidence and Risk Factors of Chemotherapy-Induced Hepatotoxicity: A Cross-Sectional Study.Cancer management and research · 2026Article
- Importance of radiation-related cognitive decline in older adults who receive cranial radiation.Expert review of anticancer therapy · 2025Review
- The concept of multidimensional frailty in geriatric oncology: a systematic scoping review.BMC geriatrics · 2025Article
- Diversity and inclusivity in oncology: A narrative review and orientation for institutional measures in Germany.Translational oncology · 2025Review
- Article
- Nanotechnology-Based Strategies for Safe and Effective Immunotherapy.Molecules (Basel, Switzerland) · 2024Review
- Prediction of moderate and severe toxicities of chemotherapy in older patients with cancer: a propensity weighted analysis of ELCAPA cohort.The oncologist · 2024Article
- Chemotherapy-Induced Peripheral Neuropathy (CIPN): A Narrative Review and Proposed Theoretical Model.Cancers · 2024Review
- Comprehensive geriatric assessment predicts radiation-induced acute toxicity in prostate cancer patients.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Liposomal irinotecan plus fluorouracil/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study.International journal of clinical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandard oncology tools are inadequate to distinguish which older patients are at higher risk of developing chemotherapy-related complications. MATERIALS AND
methodsPatients over 70 years of age starting new chemotherapy regimens were prospectively included in a multicenter study. A prechemotherapy assessment that included sociodemographics, tumor/treatment variables, and geriatric assessment variables was performed. Association between these factors and the development of grade 3-5 toxicity was examined by using logistic regression.
resultsA total of 551 patients were accrued. Chemotherapy doses (odds ratio [OR] 1.834; 95% confidence interval [CI] 1.237-2.719) and creatinine clearance (OR 0.989; 95% CI 0.981-0.997) were the only factors independently associated with toxicity. Only 19% of patients who received reduced doses of chemotherapy and had a creatinine clearance ≥40 mL/minute had grade 3-4 toxicity, compared with 38% of those who received standard doses or had a creatinine clearance <40 mL/minute (p < .0001). However, no satisfactory multivariate model was obtained using different selection approaches.
conclusionChemotherapy doses and renal function were identified as the major risk factors for developing severe toxicity in the older patient. These factors should be considered when planning to initiate a new chemotherapy regimen and should also lead to a closer follow-up in these patients. IMPLICATIONS FOR PRACTICE: Older patients are more vulnerable to chemotherapy toxicity. However, standard tools are inadequate to identify who is at higher risk of developing chemotherapy-related complications. Chemotherapy doses (standard vs. reduced) and renal function were identified as the major risk factors for developing severe toxicity in the elderly. These factors should be considered when planning to initiate a new chemotherapy regimen and should also lead to a closer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.